Drug Profile
Zolpidem - SELLAS Life Sciences
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Sanofi
- Class Acetamides; Hypnosedatives; Imidazoles; Pyridines; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease; Progressive supranuclear palsy
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Parkinson's-disease in Europe (PO)
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Progressive-supranuclear-palsy in Europe (PO)
- 27 Aug 2015 SELLAS Life Sciences plans a phase III trial for Parkinson's disease (SELLAS Life Sciences pipeline, August 2015)